CN101316822A - 作为RXR激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的1,2,3,5-四氢-环戊烯并[c]喹啉-4-酮衍生物 - Google Patents
作为RXR激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的1,2,3,5-四氢-环戊烯并[c]喹啉-4-酮衍生物 Download PDFInfo
- Publication number
- CN101316822A CN101316822A CNA2006800443323A CN200680044332A CN101316822A CN 101316822 A CN101316822 A CN 101316822A CN A2006800443323 A CNA2006800443323 A CN A2006800443323A CN 200680044332 A CN200680044332 A CN 200680044332A CN 101316822 A CN101316822 A CN 101316822A
- Authority
- CN
- China
- Prior art keywords
- compound
- optional
- disease
- replaces
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72250705P | 2005-09-30 | 2005-09-30 | |
US60/722,507 | 2005-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101316822A true CN101316822A (zh) | 2008-12-03 |
Family
ID=37625109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800443323A Pending CN101316822A (zh) | 2005-09-30 | 2006-09-25 | 作为RXR激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的1,2,3,5-四氢-环戊烯并[c]喹啉-4-酮衍生物 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1937640A2 (ja) |
JP (1) | JP2009510071A (ja) |
CN (1) | CN101316822A (ja) |
CA (1) | CA2624345A1 (ja) |
WO (1) | WO2007041076A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT1937244T (lt) | 2005-09-30 | 2018-11-12 | Io Therapeutics, Llc | Vėžio gydymas specifiniais rxr agonistais |
SI2271626T1 (sl) * | 2008-03-27 | 2015-03-31 | Janssen Pharmaceutica, N.V. | Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina |
US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
CN104114171A (zh) * | 2011-12-13 | 2014-10-22 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
AU2015207690B2 (en) * | 2014-01-14 | 2018-09-27 | Connexios Life Sciences Pvt. Ltd. | Substituted bicyclic heteroaryl compounds as RXR agonists |
GB201406486D0 (en) | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
CN115433716A (zh) | 2015-10-31 | 2022-12-06 | Io治疗公司 | 使用rxr激动剂和甲状腺激素的组合治疗神经***紊乱 |
CN115227826A (zh) | 2016-03-10 | 2022-10-25 | Io治疗公司 | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 |
WO2017155578A1 (en) | 2016-03-10 | 2017-09-14 | Io Therapeutics, Inc. | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
AU2018335393A1 (en) | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
AU2022407454A1 (en) | 2021-12-07 | 2024-06-06 | Board Of Regents, The University Of Texas System | Use of an rxr agonist in treating drug resistant her2+ cancers |
CA3242046A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048873A (en) * | 1998-10-01 | 2000-04-11 | Allergan Sales, Inc. | Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity |
-
2006
- 2006-09-25 CN CNA2006800443323A patent/CN101316822A/zh active Pending
- 2006-09-25 WO PCT/US2006/037321 patent/WO2007041076A2/en active Application Filing
- 2006-09-25 JP JP2008533489A patent/JP2009510071A/ja not_active Withdrawn
- 2006-09-25 CA CA002624345A patent/CA2624345A1/en not_active Abandoned
- 2006-09-25 EP EP06815371A patent/EP1937640A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2007041076A2 (en) | 2007-04-12 |
CA2624345A1 (en) | 2007-04-12 |
JP2009510071A (ja) | 2009-03-12 |
WO2007041076A3 (en) | 2007-06-07 |
EP1937640A2 (en) | 2008-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101316822A (zh) | 作为RXR激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的1,2,3,5-四氢-环戊烯并[c]喹啉-4-酮衍生物 | |
CN101316827A (zh) | 作为rxr激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的杂环酰胺衍生物 | |
CN101316821A (zh) | 作为rxr激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的二氢-[1h]-喹啉-2-酮衍生物 | |
CN101321747A (zh) | 作为葡萄糖激酶变构调节剂的取代的环烷基吡咯酮类 | |
CN101316836A (zh) | 作为葡萄糖激酶变构调节剂的取代的二氢异吲哚酮类 | |
US7928246B2 (en) | Dihydroisoindolones as allosteric modulators of glucokinase | |
CN101304656B (zh) | 4-((苯氧基烷基)硫代)-苯氧基乙酸衍生物的新型赖氨酸盐 | |
TW201028141A (en) | Methods of reducing small, dense LDL particles | |
CN101316837A (zh) | 作为葡萄糖激酶变构调节剂的取代的吡咯酮类 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20081203 |